Cargando…

Implementation of MenACWY vaccination because of ongoing increase in serogroup W invasive meningococcal disease, the Netherlands, 2018

The annual incidence rate of serogroup W invasive meningococcal disease in the Netherlands increased from < 0.05/100,000 (n < 10) before 2015 to 0.5/100,000 (n = 80) in 2017. Most isolates (94%) belong to clonal complex 11. The incidence rate is highest among < 5 year-olds and 15–24 year-o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knol, Mirjam J, Ruijs, Wilhelmina LM, Antonise-Kamp, Laura, de Melker, Hester E, van der Ende, Arie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	European Centre for Disease Prevention and Control (ECDC) 2018
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915972/ https://www.ncbi.nlm.nih.gov/pubmed/29692317 http://dx.doi.org/10.2807/1560-7917.ES.2018.23.16.18-00158

Ejemplares similares

Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study
por: Ohm, Milou, et al.
Publicado: (2021)

The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015–2018
por: Loenenbach, Anna D, et al.
Publicado: (2020)

Evaluation of the surveillance system for invasive meningococcal disease (IMD) in the Netherlands, 2004–2016
por: Brandwagt, Diederik A. H., et al.
Publicado: (2019)

Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines
por: Serra, Lidia, et al.
Publicado: (2021)

Tolerability of MenACWY-TT vaccination in adolescents in the Netherlands; a cross-sectional study
por: Kemmeren, J. M., et al.
Publicado: (2021)

1478. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

Modeling the public health impact of different meningococcal vaccination strategies with 4CMenB and MenACWY versus the current toddler MenACWY National Immunization Program in Chile
por: Graña, María Gabriela, et al.
Publicado: (2021)

2722 B. Efficacy and Safety of a Booster Dose of the MenACWY-TT Vaccine Administered 10 Years After Primary Vaccination with MenACWY-TT or MenACWY-PS
por: Quiambao, Beatriz, et al.
Publicado: (2019)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK
por: Hadley, Liza, et al.
Publicado: (2023)

Assessing the Role of Infant and Toddler MenACWY Immunisation in the UK: Does the Adolescent MenACWY Programme Provide Sufficient Protection?
por: Schley, Katharina, et al.
Publicado: (2023)

2459. Meningococcal ACWY (MenACWY) Vaccination of Adolescents in the United States: How Compliant Are We With the Advisory Committee on Immunization Practices (ACIP) Recommendations?
por: Cheng, Wendy, et al.
Publicado: (2018)

Modelling the impact of COVID-19 and routine MenACWY vaccination on meningococcal carriage and disease in the UK – ERRATUM
por: Hadley, Liza, et al.
Publicado: (2023)

Adolescent and parental decision-making for the MenACWY vaccination: influential predictors and parental-adolescent differences among households in the Netherlands
por: Oostdijk, C., et al.
Publicado: (2023)

Immunogenicity of MenACWY-CRM in Korean Military Recruits: Influence of Tetanus-Diphtheria Toxoid Vaccination on the Vaccine Response to MenACWY-CRM
por: Kim, Han Wool, et al.
Publicado: (2016)

Persistence of the immune response two years after vaccination with quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in Asian adolescents
por: Quiambao, Beatriz P., et al.
Publicado: (2016)

14. Postmarketing Safety Experience With MenACWY-TT
por: Serra, Lidia, et al.
Publicado: (2021)

Real-world impact and effectiveness of MenACWY-TT
por: Villena, Rodolfo, et al.
Publicado: (2023)

Necrotising fasciitis as atypical presentation of infection with emerging Neisseria meningitidis serogroup W (MenW) clonal complex 11, the Netherlands, March 2017
por: Russcher, Anne, et al.
Publicado: (2017)

Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review
por: Presa, Jessica, et al.
Publicado: (2019)

3. A Review of the Clinical Development of MenACWY-TT, a Quadrivalent Meningococcal Vaccine Conjugated to Tetanus Toxoid, in Adolescents
por: Peyrani, Paula, et al.
Publicado: (2020)

Bactericidal antibodies against hypervirulent Neisseria meningitidis C field strains following MenC-CRM or MenACWY-CRM priming and MenACWY-CRM booster in children
por: Giuliani, Marzia Monica, et al.
Publicado: (2020)

Does social deprivation correlate with meningococcal MenACWY, Hib/MenC and 4CMenB/Meningococcal Group B vaccine uptake in Northern Ireland?
por: Brennan, Orlaith C., et al.
Publicado: (2022)

A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
por: Knuf, Markus, et al.
Publicado: (2013)

Increase in invasive disease caused by Haemophilus influenzae b, the Netherlands, 2020 to 2021
por: Steens, Anneke, et al.
Publicado: (2021)

Fully Liquid MenACWY-CRM Vaccine: Results from an Integrated Safety Analysis
por: Vir Singh, Puneet, et al.
Publicado: (2022)

Correction to: A Decade of Fighting Invasive Meningococcal Disease: A Narrative Review of Clinical and Real-World Experience with the MenACWY-CRM Conjugate Vaccine
por: Ruiz Garcia, Yara, et al.
Publicado: (2021)

Response to a wild poliovirus type 2 (WPV2)-shedding event following accidental exposure to WPV2, the Netherlands, April 2017
por: Duizer, Erwin, et al.
Publicado: (2017)

Psychosocial and organizational barriers and facilitators of meningococcal vaccination (MenACWY) acceptance among adolescents and parents during the Covid-19 pandemic: a cross-sectional survey
por: Widdershoven, Veja, et al.
Publicado: (2022)

Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age
por: Marshall, Gary S., et al.
Publicado: (2022)

Immunogenicity and Safety of a Quadrivalent Meningococcal Serogroups A, C, W-135 and Y Tetanus Toxoid Conjugate Vaccine (MenACWY-TT) Administered to Adults Aged 56 Years and Older: Results of an Open-Label, Randomized, Controlled Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2013)

Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children
por: Knuf, Markus, et al.
Publicado: (2012)

Use of MenACWY-CRM Vaccine in Children Aged 2 Through 23 Months at Increased Risk for Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2013
por: MacNeil, Jessica R., et al.
Publicado: (2014)

1085 Persistence of Meningococcal Bactericidal Antibodies and Booster Response at 60-Months of Age in Children Who Received Infant Or Toddler Doses of MenACWY-CRM Conjugate Vaccine
por: Klein, Nicola P., et al.
Publicado: (2014)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra(®)) in the Republic of Korea, 2014–2019
por: Kim, Hee Soo, et al.
Publicado: (2021)

2456. Immunogenicity and Safety of a MenACWY-CRM Booster Dose 4–6 Years After Primary Quadrivalent Meningococcal Conjugate Vaccination in Healthy US Adolescents and Adults
por: Tipton, Mary, et al.
Publicado: (2018)

Wild poliovirus type 3 (WPV3)-shedding event following detection in environmental surveillance of poliovirus essential facilities, the Netherlands, November 2022 to January 2023
por: Duizer, Erwin, et al.
Publicado: (2023)

Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017
por: Krone, Manuel, et al.
Publicado: (2019)

Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands
por: Kaaijk, Patricia, et al.
Publicado: (2012)

Spillover of a hepatitis A outbreak among men who have sex with men (MSM) to the general population, the Netherlands, 2017
por: Friesema, Ingrid HM, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_khr6d7i1hft8veh1a5knud7mf9